GT Biopharma Inc
NASDAQ:GTBP
Intrinsic Value
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager pl... [ Read More ]
The intrinsic value of one GTBP stock under the Base Case scenario is 10.12 USD. Compared to the current market price of 3.7516 USD, GT Biopharma Inc is Undervalued by 63%.
Valuation Backtest
GT Biopharma Inc
Run backtest to discover the historical profit from buying and selling GTBP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
GT Biopharma Inc
Current Assets | 14.1m |
Cash & Short-Term Investments | 14m |
Other Current Assets | 84k |
Non-Current Assets | 53k |
PP&E | 53k |
Current Liabilities | 6.6m |
Accounts Payable | 4.3m |
Accrued Liabilities | 1.3m |
Other Current Liabilities | 1.1m |
Earnings Waterfall
GT Biopharma Inc
Revenue
|
0
USD
|
Operating Expenses
|
-13.6m
USD
|
Operating Income
|
-13.6m
USD
|
Other Expenses
|
6m
USD
|
Net Income
|
-7.6m
USD
|
Free Cash Flow Analysis
GT Biopharma Inc
GTBP Profitability Score
Profitability Due Diligence
GT Biopharma Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
GT Biopharma Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
GTBP Solvency Score
Solvency Due Diligence
GT Biopharma Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
GT Biopharma Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GTBP Price Targets Summary
GT Biopharma Inc
Ownership
GTBP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GTBP Price
GT Biopharma Inc
Average Annual Return | 34.72% |
Standard Deviation of Annual Returns | 201.41% |
Max Drawdown | -99% |
Market Capitalization | 5.2m USD |
Shares Outstanding | 1 380 630 |
Percentage of Shares Shorted | 0.66% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in Brisbane California, California and currently employs 8 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The firm's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The firm is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).
Contact
IPO
Employees
Officers
The intrinsic value of one GTBP stock under the Base Case scenario is 10.12 USD.
Compared to the current market price of 3.7516 USD, GT Biopharma Inc is Undervalued by 63%.